VIRX Stock Overview A clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. More details
Rewards Risk Analysis + 4 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Viracta Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Viracta Therapeutics Historical stock prices Current Share Price US$0.25 52 Week High US$1.31 52 Week Low US$0.13 Beta 0.18 1 Month Change 55.57% 3 Month Change 10.62% 1 Year Change -53.62% 3 Year Change -92.58% 5 Year Change n/a Change since IPO -98.15%
Recent News & Updates
The Listing Qualifications Department of the Nasdaq Stock Market Issues a Delist Determination to Viracta Therapeutics Dec 01
The Listing Qualifications Department of the Nasdaq Stock Market Issues a Delist Determination to Viracta Therapeutics Nov 30
Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholder Equity Requirement Nov 24
Viracta Therapeutics Receives Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market Nov 23
New major risk - Market cap size Aug 28
New major risk - Financial position Aug 15 See more updates
The Listing Qualifications Department of the Nasdaq Stock Market Issues a Delist Determination to Viracta Therapeutics Dec 01
The Listing Qualifications Department of the Nasdaq Stock Market Issues a Delist Determination to Viracta Therapeutics Nov 30
Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholder Equity Requirement Nov 24
Viracta Therapeutics Receives Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market Nov 23
New major risk - Market cap size Aug 28
New major risk - Financial position Aug 15
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan Aug 14
New major risk - Revenue and earnings growth Jun 14
Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing under Nasdaq Listing Rule 5450(a)(1) Jun 01
Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer May 15
Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
Insufficient new directors Apr 19
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial Apr 17
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan Apr 03
New major risk - Revenue and earnings growth Mar 09
Price target decreased by 20% to US$7.00 Jan 06
Viracta Therapeutics, Inc. Provides Clinical Update Jan 05
Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels Dec 04
Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC Nov 19
Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC Nov 18
New major risk - Revenue and earnings growth Nov 12
New minor risk - Share price stability Oct 06
Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer Aug 09
Price target decreased by 36% to US$9.40 Jul 06
Price target decreased by 9.1% to US$14.00 Jun 29
Viracta Therapeutics’ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma Jun 29
Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives Jan 09
Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients Dec 01
Price target decreased to US$15.00 Nov 17
High number of new directors Nov 16
High number of new directors Nov 01
High number of new directors Oct 02 Viracta Therapeutics, Inc. Announces CEO Changes
Viracta Therapeutics names Mark Rothera as new CEO Sep 19
Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment Sep 07
CEO, President & Director exercised options and sold US$54k worth of stock Aug 31
Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director Aug 27
Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors Aug 12
Viracta Therapeutics GAAP EPS of -$0.28 Aug 09 Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from Russell 2500 Value Index
Viracta Therapeutics, Inc. Provides an Update on the Phase 1b/2 Trial of Nana-Val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors Jun 03
Price target decreased to US$21.40 Apr 27
Less than half of directors are independent Apr 27
Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders Apr 16
Price target increased to US$31.50 Feb 25
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors Feb 01 Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
CEO, President & Director exercised options and sold US$133k worth of stock Dec 01
Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors Jul 23
Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma Jun 02
Viracta Therapeutics files for $200M mixed shelf offering May 28
Viracta Therapeutics, Inc. Announces Executive Changes Mar 05 Shareholder Returns VIRX US Biotechs US Market 7D 16.0% -3.3% -0.4% 1Y -53.6% -2.7% 24.8%
See full shareholder returns
Return vs Industry: VIRX underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: VIRX underperformed the US Market which returned 23.9% over the past year.
Price Volatility Is VIRX's price volatile compared to industry and market? VIRX volatility VIRX Average Weekly Movement 11.6% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: VIRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VIRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Show more Viracta Therapeutics, Inc. Fundamentals Summary How do Viracta Therapeutics's earnings and revenue compare to its market cap? VIRX fundamental statistics Market cap US$9.94m Earnings (TTM ) -US$43.29m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VIRX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$43.29m Earnings -US$43.29m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.09 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -255.6%
How did VIRX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 00:37 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Viracta Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Andrew Berens Leerink Partners LLC Hartaj Singh Oppenheimer & Co. Inc.
Show 0 more analysts 
